Literature DB >> 15842337

Detection of Candida dubliniensis in oropharyngeal samples of Turkish HIV-positive patients.

A Tekeli1, E Koyuncu, I Dolapci, G S Guven, G O Sahin, O Uzun.   

Abstract

The incidence of Candida dubliniensis in immunocomprimised patients in Turkey has not yet been determined. In this study the presence of C. dubliniensis in oral rinse samples of human immunodeficiency virus (HIV)-positive patients and healthy controls were investigated. Phenotypic tests like inability of growth at 45 degrees C, colony formation on Staib agar, intracellular beta-D-glucosidase activity, carbohydrate assimilation profiles and polymerase chain reaction with species-specific primers (DUBF and DUBR) were carried out for differentiation of C. dubliniensis. Of the 35 patients, four (11.4%) had C.dubliniensis in their oral cavity. Antifungal susceptibility testing of these C. dubliniensis isolates showed fluconazole MICs ranging from <0.06 to 32 microg ml(-1) and amphotericin B from <0.06 to 0.25 microg ml(-1). One isolate was dose-dependently susceptible to fluconazole (32 microg ml(-1)). This study demonstrates C. dubliniensis in HIV-positive patients from Turkey.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842337     DOI: 10.1111/j.1439-0507.2005.01125.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  2 in total

1.  Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.

Authors:  Carolina Rodrigues Costa; Janine Aquino de Lemos; Xisto Sena Passos; Crystiane Rodrigues de Araújo; Ana Joaquina Cohen; Lúcia Kioko Hasimoto E Souza; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2006-07       Impact factor: 2.574

Review 2.  Candida dubliniensis: epidemiology and phenotypic methods for identification.

Authors:  Erico Silva Loreto; Liliane A Scheid; Cristina W Nogueira; Gilson Zeni; Janio M Santurio; Sydney H Alves
Journal:  Mycopathologia       Date:  2010-02-21       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.